Deals Of The Week: Genentech/Constellation, Bayer/Ventana, Genzyme/Veracyte
Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.
You may also be interested in...
In the midst of a busy January – in which Ventana has signed four publicly disclosed deals to develop companion diagnostics with pharma partners – Ventana President Mara Aspinall talked with “The Pink Sheet” DAILY about pharma’s evolving attitude on personalized medicine, sharing value for joint projects and how Ventana is positioning itself to be the partner of choice for pharma.
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.
The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.